FR22C1018I1 - Anticorps egfr/c-met bispecifiques - Google Patents

Anticorps egfr/c-met bispecifiques

Info

Publication number: FR22C1018I1
Authority: FR; France
Prior art keywords: met antibodies; bispecific egfr; bispecific; egfr; antibodies
Prior art date: 2012-11-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1018C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Biotech Inc

Original Assignee

Janssen Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-21

Filing date

2022-05-11

Publication date

2022-06-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728148&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-05-11 Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc

2022-06-17 Publication of FR22C1018I1 publication Critical patent/FR22C1018I1/fr

2023-05-05 Application granted granted Critical

2023-05-05 Publication of FR22C1018I2 publication Critical patent/FR22C1018I2/fr

Status Active legal-status Critical Current

Links

102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

FR22C1018C 2012-11-21 2022-05-11 Anticorps egfr/c-met bispecifiques Active FR22C1018I2 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201261728912P	2012-11-21	2012-11-21
US201361782550P	2013-03-14	2013-03-14
US201361809541P	2013-04-08	2013-04-08
US201361864717P	2013-08-12	2013-08-12
US201361892797P	2013-10-18	2013-10-18
PCT/US2013/071288 WO2014081954A1 (fr)	2012-11-21	2013-11-21	Anticorps egfr/c-met bispécifiques

Publications (2)

Publication Number	Publication Date
FR22C1018I1 true FR22C1018I1 (fr)	2022-06-17
FR22C1018I2 FR22C1018I2 (fr)	2023-05-05

Family

ID=50728148

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR22C1018C Active FR22C1018I2 (fr)	2012-11-21	2022-05-11	Anticorps egfr/c-met bispecifiques

Country Status (32)

Country	Link
US (3)	US9593164B2 (fr)
EP (3)	EP3808767B1 (fr)
JP (5)	JP6423357B2 (fr)
KR (3)	KR20220032654A (fr)
CN (2)	CN113201073A (fr)
AU (3)	AU2013347962B2 (fr)
BR (1)	BR112015011717B1 (fr)
CA (2)	CA3182876A1 (fr)
CL (1)	CL2015001356A1 (fr)
CY (2)	CY1121270T1 (fr)
DK (2)	DK3447069T3 (fr)
EA (1)	EA031184B1 (fr)
ES (2)	ES2831374T3 (fr)
FI (1)	FIC20220016I1 (fr)
FR (1)	FR22C1018I2 (fr)
HR (2)	HRP20182128T1 (fr)
HU (3)	HUE041499T2 (fr)
IL (1)	IL238796B (fr)
LT (3)	LT2922872T (fr)
MX (1)	MX361088B (fr)
NI (1)	NI201500069A (fr)
NL (1)	NL301173I2 (fr)
NZ (1)	NZ708352A (fr)
PE (1)	PE20151181A1 (fr)
PH (1)	PH12015501118B1 (fr)
PL (1)	PL2922872T3 (fr)
PT (2)	PT2922872T (fr)
RS (2)	RS58192B1 (fr)
SG (1)	SG11201503938VA (fr)
SI (2)	SI3447069T1 (fr)
UA (1)	UA117121C2 (fr)
WO (1)	WO2014081954A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104497143B (zh)	2007-03-29	2020-08-25	健玛保	双特异性抗体及其制造方法
KR101791430B1 (ko) *	2009-11-30	2017-10-30	얀센 바이오테크 인코포레이티드	이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
EP2545077B1 (fr)	2010-03-10	2018-10-31	Genmab A/S	Anticorps monoclonaux contre c-met
WO2011131746A2 (fr) *	2010-04-20	2011-10-27	Genmab A/S	Protéines contenant des anticorps fc hétérodimères et leurs procédés de production
CN103154035B (zh)	2010-05-27	2017-05-10	根马布股份公司	针对her2的单克隆抗体
SI2771364T1 (sl)	2011-10-27	2019-10-30	Genmab As	Produkcija heterodimernih proteinov
US9695228B2 (en) *	2012-11-21	2017-07-04	Janssen Biotech, Inc.	EGFR and c-Met fibronectin type III domain binding molecules
DK3447069T3 (da) *	2012-11-21	2020-11-16	Janssen Biotech Inc	Bispecifikke egfr/c-met-antistoffer
AU2014334627B2 (en)	2013-10-14	2019-07-25	Janssen Biotech, Inc.	Cysteine engineered fibronectin type III domain binding molecules
JP6390626B2 (ja)	2014-02-04	2018-09-19	アステラス製薬株式会社	ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物
SG11201607109QA (en)	2014-02-28	2016-09-29	Merus Nv	Antibodies that bind egfr and erbb3
KR102309881B1 (ko)	2014-11-21	2021-10-06	삼성전자주식회사	c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
CN114224894A (zh) *	2014-12-03	2022-03-25	奥克兰联合服务有限公司	用于治疗癌症的激酶抑制剂前药
EP3234120A4 (fr)	2014-12-15	2018-05-16	The Regents of the University of California	Molécules cytotoxiques réagissant à des ligands intracellulaires pour la destruction sélective médiée par les lymphocytes t
WO2016100232A1 (fr) *	2014-12-15	2016-06-23	The Regents Of The University Of California	Récepteur d'antigène chimère de type porte ou bispécifique sensible à cd19 et à cd20
DK3233907T3 (da)	2014-12-19	2021-06-07	Genmab As	Bispecifikke heterodimeriske proteiner hos gnavere
CN106659779B (zh) *	2014-12-22	2021-05-18	西雅图免疫公司	双特异性四价抗体及其制造和使用方法
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
WO2016182513A1 (fr) *	2015-05-13	2016-11-17	Singapore Health Services Pte Ltd	Établissement de profils du carcinome hépatocellulaire et applications correspondantes
CN115925944A (zh)	2015-10-23	2023-04-07	美勒斯公司	抑制癌症生长的结合分子
BR112018008891A8 (pt)	2015-11-03	2019-02-26	Janssen Biotech Inc	anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
JP2019500011A (ja) *	2015-11-03	2019-01-10	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
BR112018015485A2 (pt) *	2016-02-06	2018-12-18	Epimab Biotherapeutics Inc	imunoglobulina fabs-in-tandem e usos da mesma
MX2018013413A (es)	2016-05-26	2019-06-06	Zeno Royalties & Milestones Llc	Compuestos inhibidores de egfr.
KR101985299B1 (ko) *	2016-06-03	2019-09-03	삼성전자주식회사	항-c-Met/항-Nrp1 이중 특이 항체
WO2017223180A2 (fr) *	2016-06-21	2017-12-28	Janssen Biotech, Inc.	Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
AU2017319702A1 (en)	2016-09-02	2019-04-11	The Regents Of The University Of California	Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11702480B2 (en)	2016-11-18	2023-07-18	The Regents Of The University Of California	Engineered antibodies and uses thereof
EP3554535A4 (fr)	2016-12-14	2020-10-21	Janssen Biotech, Inc.	Domaines de fibronectine de type iii se liant à pd-l1
EP3554561B1 (fr)	2016-12-14	2023-06-28	Janssen Biotech, Inc.	Domaines de fibronectine de type iii à liaison au cd137
BR112019012154A2 (pt)	2016-12-14	2019-11-12	Janssen Biotech Inc	domínios do tipo iii da fibronectina de ligação a cd8a
WO2018145048A1 (fr) *	2017-02-06	2018-08-09	Academia Sinica	Protéines recombinées et leurs utilisations
WO2018182422A1 (fr)	2017-03-31	2018-10-04	Merus N.V.	Anticorps bispécifiques de liaison à l'erbb-2 et erbb-3 destinés à être utilisés dans le traitement des cellules (f) qui présentent un gène de fusion (nrg1)
WO2018221969A1 (fr) *	2017-05-30	2018-12-06	Chong Kun Dang Pharmaceutical Corp.	Nouvel anticorps anti-c-met et son utilisation
US11479612B2 (en) *	2017-05-30	2022-10-25	Chong Kun Dang Pharmaceutical Corp.	Anti-c-Met antibody and use thereof
EP3665198A1 (fr) *	2017-08-09	2020-06-17	Merus N.V.	Anticorps qui se lient à l'egfr et à cmet
JP7250766B2 (ja) *	2017-08-25	2023-04-03	ヤンセンバイオテツク，インコーポレーテツド	ＦＣγＲＩＩ結合フィブロネクチンＩＩＩ型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子
WO2019114793A1 (fr) *	2017-12-13	2019-06-20	凯惠科技发展(上海)有限公司	Anticorps egfr, son procédé de préparation et son application
US20190184028A1 (en) *	2017-12-14	2019-06-20	Janssen Biotech, Inc.	Targeting with firbronectin type iii like domain molecules
MA52777A (fr)	2018-05-24	2021-04-14	Janssen Biotech Inc	Agents de liaison psma et utilisations correspondantes
US20200061015A1 (en)	2018-08-23	2020-02-27	Janssen Biotech, Inc.	Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
EP3849535A4 (fr) *	2018-09-10	2022-06-29	Mirati Therapeutics, Inc.	Polythérapies
CN112955137A (zh) *	2018-09-10	2021-06-11	米拉蒂治疗股份有限公司	组合疗法
SG11202103990QA (en) *	2018-10-22	2021-05-28	Janssen Pharmaceutica Nv	Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
JP2022509724A (ja)	2018-12-05	2022-01-24	ミラティセラピューティクス，インコーポレイテッド	組み合わせ療法
TW202043268A (zh) *	2018-12-18	2020-12-01	美商健生生物科技公司	產生異二聚體抗體之方法
EP3931224A4 (fr) *	2019-02-26	2023-03-01	Janssen Biotech, Inc.	Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met
CA3136888A1 (fr)	2019-04-19	2020-10-22	Janssen Biotech, Inc.	Methodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
CA3140360A1 (fr) *	2019-05-14	2020-11-19	Janssen Biotech, Inc.	Polytherapies avec des anticorps anti-egfr/c-met bispecifiques et des inhibiteurs de tyrosine kinase egfr de troisieme generation
JOP20210304A1 (ar)	2019-05-14	2023-01-30	Janssen Biotech Inc	علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
US11850248B2 (en)	2019-05-14	2023-12-26	Yuhan Corporation	Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CN114340684A (zh)	2019-09-16	2022-04-12	瑞泽恩制药公司	用于免疫pet成像的放射性标记的met结合蛋白
US11781138B2 (en)	2019-10-14	2023-10-10	Aro Biotherapeutics Company	FN3 domain-siRNA conjugates and uses thereof
EP4045061A4 (fr)	2019-10-14	2024-04-17	Aro Biotherapeutics Company	Domaines de type iii de fibronectine de liaison à cd137
JOP20220184A1 (ar) *	2020-02-12	2023-01-30	Janssen Biotech Inc	علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh)	2020-04-14	2022-03-01	美商健生生物科技公司	包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
IL300854A (en) *	2020-08-25	2023-04-01	Janssen Biotech Inc	Treatment of non-small cell lung cancer with EGFR mutations
TW202227129A (zh) *	2020-08-26	2022-07-16	美商健生生物科技公司	包括雙特異性ｅｇｆｒ／ｃ－ｍｅｔ抗體之穩定調配物
EP4210702A1 (fr)	2020-09-14	2023-07-19	JANSSEN Pharmaceutica NV	Thérapies combinées d'inhibiteurs de fgfr
KR20230137393A (ko)	2021-01-28	2023-10-04	얀센 바이오테크 인코포레이티드	Psma 결합 단백질 및 이의 용도
CN116997358A (zh) *	2021-03-09	2023-11-03	詹森生物科技公司	对缺失egfr激活突变的癌症的治疗
TW202309094A (zh)	2021-05-18	2023-03-01	美商健生生物科技公司	用於識別癌症患者以進行組合治療之方法
TW202317635A (zh) *	2021-07-14	2023-05-01	大陸商江蘇恆瑞醫藥股份有限公司	特異性結合ｈｇｆｒ和ｅｇｆｒ的抗原結合分子及其醫藥用途
WO2023069888A1 (fr) *	2021-10-18	2023-04-27	Tavotek Biotherapeutics (Hong Kong) Limited	Anticorps anti-egfr, anticorps anti-cmet, anticorps anti-vegf, anticorps multispécifiques et leurs utilisations
US20230183360A1 (en) *	2021-12-09	2023-06-15	Janssen Biotech, Inc.	Use of Amivantamab to Treat Colorectal Cancer
TW202342057A (zh)	2022-02-07	2023-11-01	美商健生生物科技公司	用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
CN114740108B (zh) *	2022-03-28	2023-07-14	天津键凯科技有限公司	一种聚合物修饰抗体类药物的修饰度的测定方法
WO2024002235A1 (fr) *	2022-06-29	2024-01-04	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anticorps anti-egfr/met et leurs utilisations
WO2024003837A1 (fr) *	2022-06-30	2024-01-04	Janssen Biotech, Inc.	Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou œsophagien

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
CA2066428C (fr)	1989-09-08	2000-11-28	Bert Vogelstein	Modifications de la structure du gene recepteur du facteur de croissance epidermique dans les gliomes humains
DK0494955T3 (da)	1989-10-05	1998-10-26	Optein Inc	Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
HU219537B (hu)	1991-03-06	2001-05-28	Merck Patent Gmbh.	Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
WO1993011236A1 (fr)	1991-12-02	1993-06-10	Medical Research Council	Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
WO1994012520A1 (fr)	1992-11-20	1994-06-09	Enzon, Inc.	Segment de liaison pour polypeptides fusionnes lies
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
AUPO591797A0 (en)	1997-03-27	1997-04-24	Commonwealth Scientific And Industrial Research Organisation	High avidity polyvalent and polyspecific reagents
ES2301198T3 (es)	1997-06-12	2008-06-16	Novartis International Pharmaceutical Ltd.	Polipeptidos artificiales de anticuerpos.
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6472147B1 (en)	1999-05-25	2002-10-29	The Scripps Research Institute	Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en)	2000-04-27	2013-08-29	Networth Services, Inc.	Systems and methods for determining the financial status of bonds
DK2163256T3 (en)	2001-05-11	2015-12-07	Ludwig Inst For Cancer Res Ltd	Specific binding proteins and use thereof
US7595378B2 (en)	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CZ200438A3 (cs) *	2001-06-13	2004-06-16	Genmab A/S	Název neuveden
EP1283053A1 (fr)	2001-08-09	2003-02-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibiteurs de l'activité de HER3
JP4602614B2 (ja)	2001-09-26	2010-12-22	アイシン精機株式会社	自動車用ドア
US7842476B2 (en)	2002-09-06	2010-11-30	Isogenica Limited	In vitro peptide expression library
BRPI0407446A (pt)	2003-02-13	2006-01-31	Pharmacia Corp	Anticorpos para c-met para o tratamento de cânceres
CN103880955A (zh) *	2003-07-18	2014-06-25	安姆根有限公司	肝细胞生长因子的特异性结合物
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
AU2005250484B2 (en)	2004-06-04	2011-08-11	Genentech, Inc.	EGFR mutations
NZ552485A (en)	2004-08-05	2009-11-27	Genentech Inc	Humanized anti-cmet antagonists
JP2008511337A (ja)	2004-09-02	2008-04-17	ジェネンテック・インコーポレーテッド	ヘテロ多量体分子
JP5620626B2 (ja)	2005-03-31	2014-11-05	中外製薬株式会社	会合制御によるポリペプチド製造方法
DE102005028778A1 (de)	2005-06-22	2006-12-28	SUNJÜT Deutschland GmbH	Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (fr)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production d'anticorps bispécifiques
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
ES2529790T3 (es)	2007-04-13	2015-02-25	Dana-Farber Cancer Institute, Inc.	Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
US20090042906A1 (en)	2007-04-26	2009-02-12	Massachusetts Institute Of Technology	Methods for treating cancers associated with constitutive egfr signaling
US20110256142A1 (en)	2007-09-06	2011-10-20	Genmab A/S	Novel methods and antibodies for treating cancer
US8748356B2 (en)	2007-10-19	2014-06-10	Janssen Biotech, Inc.	Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en)	2007-12-19	2009-07-09	Centocor Ortho Biotech Inc.	Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US20110118144A1 (en)	2007-12-19	2011-05-19	Linus Hyun	Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
CN102014913A (zh)	2008-03-06	2011-04-13	健泰科生物技术公司	C-met和egfr拮抗剂的联合疗法
PE20091827A1 (es)	2008-04-11	2009-11-20	Galaxy Biotech Llc	Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
PE20120015A1 (es) *	2008-08-15	2012-01-26	Merrimack Pharmaceuticals Inc	Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
CA2738583A1 (fr)	2008-10-01	2010-04-08	Ludwig Institute For Cancer Research	Methodes de traitement du cancer
US8278419B2 (en)	2008-10-31	2012-10-02	Centocor Ortho Biotech Inc.	Fibronectin type III domain based scaffold compositions, methods and uses
US8545839B2 (en) *	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
US20100173013A1 (en) *	2009-01-08	2010-07-08	Denis Drygin	Treatment of neoplastic disorders using combination therapies
KR20110124368A (ko)	2009-04-07	2011-11-16	로슈 글리카트 아게	이중특이적 항―ｅｒｂｂ―２／항―ｃ―ｍｅｔ 항체
ES2708124T3 (es)	2009-04-27	2019-04-08	Oncomed Pharm Inc	Procedimiento para preparar moléculas heteromultiméricas
IN2012DN02737A (fr) *	2009-09-01	2015-09-11	Abbott Lab
KR101791430B1 (ko)	2009-11-30	2017-10-30	얀센 바이오테크 인코포레이티드	이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
EP2545077B1 (fr) *	2010-03-10	2018-10-31	Genmab A/S	Anticorps monoclonaux contre c-met
WO2011131746A2 (fr) *	2010-04-20	2011-10-27	Genmab A/S	Protéines contenant des anticorps fc hétérodimères et leurs procédés de production
BR112012027863B1 (pt)	2010-04-30	2023-03-07	Janssen Biotech, Inc	Polipeptídeos, arcabouços de proteína, bibliotecas e métodos de construção das mesmas, método para gerar uma ligação de arcabouço de proteína a um alvo específico com uma afinidade de ligação predefinida, moléculas de ácido nucleico isolada, vetores, células hospedeiras, composições, dispositivos médicos, e artigos de fabricação
WO2011158061A1 (fr) *	2010-06-15	2011-12-22	Alberto Bardelli	Le gène mlk4, un nouveau marqueur de diagnostic et de pronostic des cancers
EP2621953B1 (fr)	2010-09-30	2017-04-05	Ablynx N.V.	Matières biologiques associées à c-met
EP2635607B1 (fr)	2010-11-05	2019-09-04	Zymeworks Inc.	Conception d'anticorps hétérodimérique stable ayant des mutations dans le domaine fc
JP6076357B2 (ja) *	2011-10-10	2017-02-08	シティ・オブ・ホープＣｉｔｙｏｆＨｏｐｅ	メディトープおよびメディトープ結合性抗体ならびにそれらの使用
JP6326371B2 (ja)	2011-11-04	2018-05-16	ザイムワークス，インコーポレイテッド	Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
DK3447069T3 (da) *	2012-11-21	2020-11-16	Janssen Biotech Inc	Bispecifikke egfr/c-met-antistoffer
US9695228B2 (en)	2012-11-21	2017-07-04	Janssen Biotech, Inc.	EGFR and c-Met fibronectin type III domain binding molecules

2013
- 2013-11-21 DK DK18199421.1T patent/DK3447069T3/da active
- 2013-11-21 LT LTEP13856592.4T patent/LT2922872T/lt unknown
- 2013-11-21 SI SI201331820T patent/SI3447069T1/sl unknown
- 2013-11-21 RS RS20181488A patent/RS58192B1/sr unknown
- 2013-11-21 PT PT13856592T patent/PT2922872T/pt unknown
- 2013-11-21 EP EP20197551.3A patent/EP3808767B1/fr active Active
- 2013-11-21 EP EP13856592.4A patent/EP2922872B1/fr active Active
- 2013-11-21 RS RS20201373A patent/RS61057B1/sr unknown
- 2013-11-21 CN CN202110097790.XA patent/CN113201073A/zh active Pending
- 2013-11-21 AU AU2013347962A patent/AU2013347962B2/en active Active
- 2013-11-21 HU HUE13856592A patent/HUE041499T2/hu unknown
- 2013-11-21 LT LTEP18199421.1T patent/LT3447069T/lt unknown
- 2013-11-21 PT PT181994211T patent/PT3447069T/pt unknown
- 2013-11-21 PL PL13856592T patent/PL2922872T3/pl unknown
- 2013-11-21 NZ NZ70835213A patent/NZ708352A/en unknown
- 2013-11-21 KR KR1020227007572A patent/KR20220032654A/ko not_active IP Right Cessation
- 2013-11-21 CN CN201380071081.8A patent/CN104955838B/zh active Active
- 2013-11-21 HU HUE18199421A patent/HUE052548T2/hu unknown
- 2013-11-21 BR BR112015011717-1A patent/BR112015011717B1/pt active IP Right Grant
- 2013-11-21 SI SI201331221T patent/SI2922872T1/sl unknown
- 2013-11-21 MX MX2015006387A patent/MX361088B/es active IP Right Grant
- 2013-11-21 KR KR1020237044846A patent/KR20240005211A/ko active Application Filing
- 2013-11-21 EP EP18199421.1A patent/EP3447069B1/fr active Active
- 2013-11-21 EA EA201590985A patent/EA031184B1/ru unknown
- 2013-11-21 CA CA3182876A patent/CA3182876A1/fr active Pending
- 2013-11-21 PE PE2015000666A patent/PE20151181A1/es active IP Right Grant
- 2013-11-21 ES ES18199421T patent/ES2831374T3/es active Active
- 2013-11-21 CA CA2893505A patent/CA2893505C/fr active Active
- 2013-11-21 JP JP2015544134A patent/JP6423357B2/ja active Active
- 2013-11-21 DK DK13856592.4T patent/DK2922872T3/da active
- 2013-11-21 ES ES13856592T patent/ES2700231T3/es active Active
- 2013-11-21 SG SG11201503938VA patent/SG11201503938VA/en unknown
- 2013-11-21 US US14/086,588 patent/US9593164B2/en active Active
- 2013-11-21 UA UAA201506064A patent/UA117121C2/uk unknown
- 2013-11-21 KR KR1020157016321A patent/KR102373193B1/ko active IP Right Grant
- 2013-11-21 WO PCT/US2013/071288 patent/WO2014081954A1/fr active Application Filing
2014
- 2014-05-21 US US14/283,257 patent/US9580508B2/en active Active
2015
- 2015-05-13 IL IL238796A patent/IL238796B/en active IP Right Grant
- 2015-05-19 CL CL2015001356A patent/CL2015001356A1/es unknown
- 2015-05-20 NI NI201500069A patent/NI201500069A/es unknown
- 2015-05-20 PH PH12015501118A patent/PH12015501118B1/en unknown
2016
- 2016-12-21 US US15/386,195 patent/US9695242B2/en active Active
2018
- 2018-10-17 JP JP2018195580A patent/JP6773746B2/ja active Active
- 2018-12-17 HR HRP20182128TT patent/HRP20182128T1/hr unknown
- 2018-12-27 CY CY20181101400T patent/CY1121270T1/el unknown
2019
- 2019-01-23 AU AU2019200441A patent/AU2019200441B2/en active Active
2020
- 2020-10-01 JP JP2020167062A patent/JP7019771B2/ja active Active
- 2020-11-19 CY CY20201101101T patent/CY1123550T1/el unknown
- 2020-11-20 HR HRP20201848TT patent/HRP20201848T1/hr unknown
2021
- 2021-04-20 AU AU2021202394A patent/AU2021202394B2/en active Active
2022
- 2022-02-01 JP JP2022014503A patent/JP7397105B2/ja active Active
- 2022-05-02 NL NL301173C patent/NL301173I2/nl unknown
- 2022-05-04 HU HUS2200016C patent/HUS2200016I1/hu unknown
- 2022-05-11 FR FR22C1018C patent/FR22C1018I2/fr active Active
- 2022-05-31 FI FIC20220016C patent/FIC20220016I1/fi unknown
- 2022-06-06 LT LTPA2022507C patent/LTPA2022507I1/lt unknown
2023
- 2023-11-30 JP JP2023203256A patent/JP2024026236A/ja active Pending

Also Published As

Publication number	Publication date
CA2893505C (fr)	2023-02-21
FR22C1018I2 (fr)	2023-05-05
LTPA2022507I1 (fr)	2022-06-27
EA031184B1 (ru)	2018-11-30
JP2022062155A (ja)	2022-04-19
EA201590985A1 (ru)	2015-11-30
PT3447069T (pt)	2020-11-13
EP2922872A1 (fr)	2015-09-30
AU2021202394B2 (en)	2024-03-07
MX361088B (es)	2018-11-26
AU2019200441B2 (en)	2021-01-28
EP3808767C0 (fr)	2023-12-06
KR102373193B1 (ko)	2022-03-10
NL301173I2 (nl)	2022-06-15
HUE052548T2 (hu)	2021-05-28
US20140141000A1 (en)	2014-05-22
CN104955838A (zh)	2015-09-30
WO2014081954A1 (fr)	2014-05-30
EP3808767A1 (fr)	2021-04-21
JP2016505537A (ja)	2016-02-25
HUS2200016I1 (hu)	2022-05-28
US20140255408A1 (en)	2014-09-11
CA3182876A1 (fr)	2014-05-30
BR112015011717B1 (pt)	2023-12-12
EP3447069B1 (fr)	2020-09-23
IL238796B (en)	2019-06-30
ES2831374T3 (es)	2021-06-08
AU2013347962A1 (en)	2015-05-28
JP2019048817A (ja)	2019-03-28
BR112015011717A2 (pt)	2017-08-15
JP7019771B2 (ja)	2022-02-15
CY1123550T1 (el)	2022-03-24
CN104955838B (zh)	2021-02-02
EP3808767B1 (fr)	2023-12-06
US9580508B2 (en)	2017-02-28
AU2013347962B2 (en)	2018-10-25
LT3447069T (lt)	2020-12-10
US20170101475A1 (en)	2017-04-13
HUE041499T2 (hu)	2019-05-28
NI201500069A (es)	2015-10-19
NZ708352A (en)	2019-10-25
FIC20220016I1 (fi)	2022-05-31
PE20151181A1 (es)	2015-08-19
UA117121C2 (uk)	2018-06-25
HRP20201848T1 (hr)	2021-01-08
SI2922872T1 (sl)	2019-01-31
PT2922872T (pt)	2019-01-18
PH12015501118A1 (en)	2016-02-01
CA2893505A1 (fr)	2014-05-30
RS58192B1 (sr)	2019-03-29
PH12015501118B1 (en)	2016-02-01
NL301173I1 (nl)	2022-05-04
US9593164B2 (en)	2017-03-14
JP6423357B2 (ja)	2018-11-14
AU2019200441A1 (en)	2019-02-07
JP6773746B2 (ja)	2020-10-21
SI3447069T1 (sl)	2021-02-26
SG11201503938VA (en)	2015-06-29
AU2021202394A1 (en)	2021-05-20
CL2015001356A1 (es)	2015-11-06
IL238796A0 (en)	2015-06-30
KR20220032654A (ko)	2022-03-15
KR20150087365A (ko)	2015-07-29
US9695242B2 (en)	2017-07-04
KR20240005211A (ko)	2024-01-11
JP2021006561A (ja)	2021-01-21
LT2922872T (lt)	2018-12-27
HRP20182128T1 (hr)	2019-02-08
JP2024026236A (ja)	2024-02-28
DK2922872T3 (da)	2019-01-02
RS61057B1 (sr)	2020-12-31
CN113201073A (zh)	2021-08-03
CY1121270T1 (el)	2020-05-29
DK3447069T3 (da)	2020-11-16
JP7397105B2 (ja)	2023-12-12
EP3447069A1 (fr)	2019-02-27
PL2922872T3 (pl)	2019-03-29
EP2922872B1 (fr)	2018-10-10
EP2922872A4 (fr)	2016-07-06
ES2700231T3 (es)	2019-02-14
MX2015006387A (es)	2015-12-03

Publication	Publication Date	Title
FR22C1018I2 (fr)	2023-05-05	Anticorps egfr/c-met bispecifiques
FR23C1023I2 (fr)	2024-03-29	Anticorps anti-il-36r
DK2934584T3 (da)	2020-05-18	Anti-gdf15-antistoffer
DK2850101T3 (da)	2019-07-15	Anti-FcRn-antistoffer
DK2858671T3 (da)	2019-10-21	Antistofformulering
DK2890397T3 (da)	2019-08-05	Antiprolactinreceptor-antistofformulering
DK3117837T3 (da)	2019-08-19	Antistofformuleringer
DK2847231T3 (da)	2019-10-14	Multispecifikke monoklonale antistoffer
DK2680500T3 (da)	2020-01-02	Programregistrering
BR112013010687A2 (pt)	2016-08-02	combinações de anticorpos c-met
BR112014025037A2 (pt)	2018-07-31	anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
BR112014031335A2 (pt)	2017-06-27	bloco de diagnóstico transacional
DK2828292T3 (da)	2019-01-02	Jcv-neutraliserende antistoffer
DK2934582T3 (da)	2020-02-24	Anti-her2-antistofformulering
DK2931748T3 (da)	2017-01-02	Bmp-6-antistoffer
DK3431504T3 (da)	2021-06-28	Antiphospholipase d4-antistof
CL2014003125A1 (es)	2015-08-21	Anticuerpos de anti-transglutaminasa 2
DE112013004839A5 (de)	2015-06-25	Antriebsstrang
DK2935330T3 (da)	2019-07-22	Anti-notch3-antistoffer
FI20126323L (fi)	2014-06-19	Pilarikenkä
AU2024203417A1 (en)	2024-06-13	Bispecific EGFR/c-Met antibodies
FR2991965B1 (fr)	2014-11-28	Pedalier alternatif vertical
TH1401003801B (th)	2016-03-21	ข้อต่อ
ES1077468Y (es)	2012-10-24	Saco de Rafia